Research Study for Chronic Kidney Disease and High Blood Pressure
About this study
Do you suffer from Chronic Kidney Disease (CKD) and Hypertension (HTN)?
This clinical research study is looking at the safety and effectiveness of an investigational medication option for volunteers with chronic kidney disease.
The purpose of this study is to investigate the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin, compared with placebo and dapagliflozin, in reducing the risk of the composite of > 50% decline in eGFR, kidney failure, or CV death, in individuals with CKD and HTN.
This study consists of a 4-week dapagliflozin Run-in Period for participants untreated with SGLT2i at screening, and a double-blinded period where participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin.
Site visits will take place at 2-, 4-, 8-, 16-, 34, and 52-weeks following randomization. Thereafter visits will occur approximately every 4 months.
Would you like to take part in CKD Research?
As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow up of your condition to monitor the safety and effectiveness of the care you’ll receive. Study volunteers are an important part of moving medical care forward.
Who may qualify
- Are of any sex and gender ≥ 18 years of age at the time of signing the informed consent.
- Have:
- eGFR ≥ 30 and < 60 mL/min/1.73 m2 (local or central laboratory values) AND UACR ≥ 30 mg/g (3.39 mg/mmol) and < 500 mg/g (56.5 mg/mmol) (central laboratory values only), or
- eGFR ≥ 30 and ≤ 75 mL/min/1.73 m2 (local or central laboratory values) AND UACR ≥ 500 mg/g (56.5 mg/mmol) and ≤ 5000 mg/g (565 mg/mmol) or UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local or central laboratory values).
- Have a history of HTN and a SBP ≥ 130 mmHg (the most recent value within 4 weeks prior to screening or at the Screening Visit) and ≥ 120 mmHg at the Randomisation Visit.
- Are on a stable and maximum tolerated dose of an ACEi or an ARB (not both) for at least 4 weeks prior to Screening Visit.
- Have:
- Serum or plasma potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR ≥ 45 mL/min/1.73 m2 (local or central laboratory values).
- Serum or plasma potassium ≥ 3.0 and ≤ 4.5 mmol/L if eGFR < 45 mL/min/1.73 m2 (local or central laboratory values)
- Have systolic blood pressure > 180 mmHg, or diastolic BP > 110 mmHg at screening.
- Have known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months prior to screening.
- Have serum sodium < 135 mmol/L (central or local laboratory values obtained within 4 weeks prior to screening or at the Screening Visit).
- Have type 1 diabetes mellitus
- Have uncontrolled type 2 diabetes mellitus with HbA1c > 10.5% (> 91 mmol/mol) (central or local laboratory values obtained within 3 months prior to screening or at the Screening Visit).
- Display New York Heart Association functional HF class IV at screening.
- Have had any stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening heart failure within previous 3 months prior to randomisation.
- Have documented history of adrenal insufficiency.
- Have had any dialysis (including for acute kidney injury) within 3 months prior to Screening Visit.
- Have had any acute kidney injury within 3 months prior to the Screening Visit.
- Have a history of organ transplant or bone marrow transplant, or planned organ transplant within 6 months following randomisation (including kidney transplant).
- Have had any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months prior to Visit 1).
What participation may involve
- Regular visits with the study team at no cost
- Study assessments and health monitoring throughout
- Check-ins between visits
- Informed consent before anything begins — questions welcome
What participants may receive
- Study-related care from a physician-led team
- Study assessments at no cost
- Reimbursement for reasonable travel, where applicable
Where this study is enrolling
Learn more
Chronic Kidney Disease
Your kidneys filter waste and extra fluid out of the blood, help control blood pressure, and keep minerals in balance. Chronic kidney disease means that filtering has been…
Read about this condition →Kidney and Liver Diseases
The kidneys filter your blood and keep fluid and minerals in balance. The liver processes food, medicines and waste, and makes proteins your body needs every day. Both…
Read about this condition →Hypertension (high blood pressure)
Blood pressure is the force of blood pushing against the walls of your arteries. Hypertension, or high blood pressure, means that force stays higher than it should over…
Read about this condition →Cardiovascular disease
Cardiovascular disease is a group of conditions affecting the heart and the blood vessels that carry blood around your body. The most common form in Canada is ischemic…
Read about this condition →
Other studies you can explore
All current studies →
RecruitingA Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight Without Type 2 DiabetesSarniaCheck availability →
RecruitingStudy of Orforglipron in Participants With Peripheral Artery DiseaseMontrealCheck availability →
RecruitingA Study for Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney DiseaseSarnia · MontrealCheck availability →